Understanding the AI-enabled drug discovery landscape

8 July 2022

An Expert View from Henrietta Bull, business and marketing analyst, and Robert Thong, chief executive, MultiOmic Health.

AI-enabled drug discovery companies (AIDDs) have taken the bioscience world by storm, raising more than $5.2 billion from investors in 2021, while 15 AI-enabled candidate drugs are in clinical trials, plus more than 150 at the preclinical stage1 . With hundreds of AIDDs worldwide, ranging from listed companies to brand new startups, how does one make sense of them? This article suggests some dimensions to help potential pharma collaborators or prospective investors differentiate AIDDs.

AIDDs can first be distinguished by their drug discovery role. “Treatment Concept Generators” determine where and how in the body’s complex system to intervene. Whereas “Intervention Engineers” design or improve the physical interventions. Some AIDDs do combination. Secondly, AIDDs adopt different Commercial Models.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK